Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 21

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 21
---
 a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and directors was included by a target business as a condition to any agreement with respect to our initial business combination. As more fully discussed in “ Management — Conflicts of Interest,” if any of our officers or directors becomes aware of an initial business combination opportunity that might be attractive to any entity to which he or she has pre -existingfiduciary or contractual obligations, he or she may be required to present such initial business combination opportunity to such entity prior to presenting such initial business combination opportunity to us. Certain of our other officers and directors currently may have certain relevant pre -existingfiduciary duties or contractual obligations. For more information on the relevant pre -existingfiduciary duties or contractual obligations of our management team, see “ Management — Conflicts of Interest.” In addition, some of our officers and directors, including our Executive Chair, Chief Executive Officer and Chief Financial Officer, may participate in the formation of, or become an officer or director of, additional blank check companies prior to completion of our initial business combination. As a result, our officers and/or directors may have conflicts of interest in determining whether to present business combination opportunities to us or to any other blank check company with which they may become involved and could have additional conflicts in the future. Private Placements On June 17, 2024, we issued to the sponsor an aggregate of 22,361,111 ordinary shares for an aggregate purchase price of $35,000, or approximately $0.0016 per share. On November6, 2024, the sponsor surrendered and forfeited 12,503,968 ordinary shares to us for no consideration, following which the sponsor holds 9,857,143 ordinary shares, which we refer to throughout this prospectus as the “founder shares.” The founder shares held by the sponsor includes an aggregate of up to 1,285,714shares subject to surrender and forfeiture to the extent that the underwriters’ over -allotmentoption is not exercised in full or in part, so that the sponsor will continue to own 30% of our issued and outstanding shares after this offering (not including the private units and the representative shares described below and assuming the sponsor does not purchase units in this offering). In addition, the sponsor has agreed that they and/or their designees will purchase from us an aggregate of 400,000 units at a price of $10.00 per unit, for an aggregate purchase price of